Welcome to LookChem.com Sign In|Join Free
  • or
(R)-5-(3-chlorophenyl)-3-(1-((4-Methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)oxy)ethyl)isoxazole, also known as AZD 2066, is a chiral organic compound with a complex molecular structure. It features a 3-chlorophenyl group, an isoxazole ring, and a 4H-1,2,4-triazole moiety connected through an ethyloxy linker. The presence of a methyl group on the triazole and a pyridine ring further contributes to its unique properties. AZD 2066 is a potent and selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), making it a promising candidate for various therapeutic applications.

934282-55-0

Post Buying Request

934282-55-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

934282-55-0 Usage

Uses

Used in Pharmaceutical Industry:
AZD 2066 is used as a mGluR5 antagonist for treating and preventing pain, neurological, psychiatric, and other diseases. Its ability to selectively target the mGluR5 receptor modulates glutamate signaling, which plays a crucial role in various neurological and psychiatric disorders. By inhibiting mGluR5, AZD 2066 can potentially alleviate symptoms and improve the quality of life for patients suffering from these conditions.
Used in Neurological Applications:
In the neurological field, AZD 2066 is used as a therapeutic agent for treating conditions such as anxiety, depression, and schizophrenia. The modulation of mGluR5 activity by AZD 2066 can help regulate the excitatory neurotransmission, leading to a reduction in the symptoms associated with these disorders.
Used in Pain Management:
AZD 2066 is also used in pain management, particularly for chronic and neuropathic pain conditions. The mGluR5 receptor plays a role in the processing and modulation of pain signals in the central nervous system. By antagonizing this receptor, AZD 2066 can potentially reduce pain perception and provide relief to patients suffering from various types of pain.
Used in Drug Discovery and Development:
In addition to its direct therapeutic applications, AZD 2066 serves as a valuable tool in drug discovery and development. Its selective antagonism of the mGluR5 receptor can be used to study the role of this receptor in various physiological and pathological processes. This knowledge can contribute to the development of new drugs targeting the mGluR5 receptor or related pathways for the treatment of neurological and psychiatric disorders.

Check Digit Verification of cas no

The CAS Registry Mumber 934282-55-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,2,8 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 934282-55:
(8*9)+(7*3)+(6*4)+(5*2)+(4*8)+(3*2)+(2*5)+(1*5)=180
180 % 10 = 0
So 934282-55-0 is a valid CAS Registry Number.

934282-55-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-(3-chlorophenyl)-3-[(1R)-1-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)oxy]ethyl]-1,2-oxazole

1.2 Other means of identification

Product number -
Other names UNII-MQ908Y1ZB2

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:934282-55-0 SDS

934282-55-0Relevant academic research and scientific papers

COMPOUNDS 501

-

Page/Page column 3, (2010/03/04)

The present invention relates to a novel crystalline form of 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatm

A NEW CRYSTALLINE FORM OF 4- (5- { (IR) -1- [5- (3- CHLOROPHENYL) ISOXAZOL-3-YL] ETHOXY } -4-METHYL-4H-L, 2, 4- TRIAZOL-3-YL) PYRIDINE

-

Page/Page column 9, (2010/04/03)

The present invention relates to a novel crystalline form of 4- (5-{ (IR) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy } -4- methyl-4H-l, 2, 4-triazol-3-yl) pyridine. Further, the present invention also relates to the use of the novel crystalline form f

5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS

-

Page/Page column 16; 25, (2008/06/13)

The present invention is directed to novel compounds of formula (I) / (I1) / (III), their use in therapy and pharmaceutical compositions comprising said novel compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 934282-55-0